Strona 4 - Najlepsi lekarze do leczenia raka jelita cienkiego – TOP 116 lekarzy

Dr Muzaffer Al specjalizuje się w chirurgii laparoskopowej raka jelita cienkiego. Ukończył zaawansowane szkolenia w ramach wiodących programów medycznych Uniwersytetu Stambulskiego.

• Certyfikowany chirurg z ponad 20-letnim doświadczeniem
• Ekspert w dziedzinie laparoskopowej chirurgii antyrefluksowej i bariatrycznej
• Przeszkolony w zakresie chirurgii onkologicznej na Wydziale Medycyny Cerrahpaşa

Profesor onkologii radioterapeutycznej z ponad 20-letnim doświadczeniem w leczeniu nowotworów – obecnie pracuje na Uniwersytecie Medipol w Stambule.

• Kształcił się na Uniwersytecie Stambulskim oraz Uniwersytecie Kadir Has
• Był profesorem nadzwyczajnym, a następnie profesorem zwyczajnym na Uniwersytecie Demiroglu Bilim
• Pracuje na oddziałach onkologii radioterapeutycznej w wiodących szpitalach w Stambule
• Zajmuje się złożonymi przypadkami wymagającymi precyzyjnej radioterapii

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

33 lata specjalizacji w onkologii i radioterapii – dr Auala Hubert kieruje Centrum Raka Układu Pokarmowego w Centrum Medycznym Hadassah.

• Posiada certyfikat specjalisty w dziedzinie onkologii i radioterapii
• Ukończył Szpital Uniwersytecki Hadassah
• Biegle posługuje się językiem angielskim i hebrajskim
• Jest członkiem licznych towarzystw onkologicznych

Doc. dr Nail Paksoy specjalizuje się w nowotworach układu pokarmowego w szpitalu Medipol Bahçelievler, ze szczególnym uwzględnieniem raka jelita cienkiego.

• Posiada certyfikat ESMO w dziedzinie onkologii klinicznej
• Współbadacz w 8 międzynarodowych badaniach klinicznych nad metodami leczenia raka
• Autor licznych prac naukowych na temat nowotworów układu pokarmowego i rzadkich typów raka
• Odbył staż specjalistyczny w Instytucie Onkologii Uniwersytetu Stambulskiego

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr Alemdar specjalizuje się w leczeniu raka jelita cienkiego. Odbył on zaawansowane szkolenie w zakresie onkologii klinicznej na Uniwersytecie Akdeniz.

• Posiada certyfikat specjalisty onkologii klinicznej od 2018 roku
• Ponad 15 lat doświadczenia w chorobach wewnętrznych i onkologii
• Pracował w Szpitalu Uniwersyteckim Akdeniz — wiodącym ośrodku onkologicznym
• Członek Tureckiego Towarzystwa Onkologii Klinicznej

Ponad 30 lat doświadczenia w immunologii ze szczególnym uwzględnieniem wiroterapii — dr Jaunalksne kieruje Centrum Immunologii Klinicznej w Szpitalu Uniwersyteckim im. Paula Stradinsa.

• Specjalizuje się w jednej z najnowocześniejszych dziedzin immunologii
• Absolwentka Ryskiego Instytutu Medycznego
• Ukończyła staż specjalizacyjny w zakresie chorób wewnętrznych

Doktor Ozden łączy wykształcenie akademickie zdobyte na prestiżowym Wydziale Cerrahpaşa Uniwersytetu Stambulskiego z 6-letnią specjalizacją w dziedzinie onkologii klinicznej.

• Posiada certyfikat specjalisty w dziedzinie chorób wewnętrznych i onkologii klinicznej
• Szkolił się na Uniwersytecie Kocaeli, znanym z zaawansowanych metod leczenia nowotworów
• Posiada ponad 15-letnie doświadczenie kliniczne zdobyte w wielu szpitalach

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Dr Kinas specjalizuje się w leczeniu złożonych nowotworów układu pokarmowego, w tym raka jelita cienkiego, w szpitalach Büyük Anadolu.

• Posiada doświadczenie w chirurgii trzustki i dróg żółciowych
• Wykonuje operacje onkologiczne w przypadku różnych nowotworów układu pokarmowego
• Specjalizuje się w zaawansowanych zabiegach bariatrycznych i metabolicznych

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.

He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.

Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.

Przeprowadził ponad 15 000 zabiegów chirurgicznych, w tym 1 000 operacji małoinwazyjnych rocznie — dr de Lacy jest pionierem chirurgii układu pokarmowego w szpitalu Quiron Barcelona.

• Specjalizuje się w leczeniu raka odbytnicy, jelita grubego oraz przełyku
• Jako pierwszy na świecie wykonał usunięcie pęcherzyka żółciowego przez usta
• Wprowadził technikę TaTME w chirurgii raka odbytnicy
• Pełni funkcję prezesa Stowarzyszenia Chirurgów Endoskopistów w Europie